Price
CHART BY
Frequently asked questions
What is Sernova's market capitalization?
The market capitalization of Sernova is $51.22M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Sernova?
Sernova's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.0728. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Sernova's stock?
Currently, 3 analysts cover Sernova's stock, with a consensus target price of $1.016. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Sernova?
Sernova's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$21.69M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Sernova?
Sernova has a free cash flow of -$13.09M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Sernova have, and what sector and industry does it belong to?
Sernova employs approximately 17 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Sernova's shares?
The free float of Sernova is 314.88M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $51.22M
- EPS (TTM)
- -$0.0728
- Free Float
- 314.88M
- EBITDA (TTM)
- -$21.69M
- Free Cashflow (TTM)
- -$13.09M
Pricing
- 1D span
- $0.154$0.16
- 52W span
- $0.146$0.519
Analyst Ratings
The price target is $1.016 and the stock is covered by 3 analysts.
Buy
3
Hold
0
Sell
0
Information
Sernova Corp. is a clinical-stage biotechnology company, which engages in advancing regenerative medicine in the treatment of chronic diseases. It focuses on its proprietary Cell Pouch, a bio-hybrid organ system which is designed to enhance the delivery of cell therapy to better replicate natural body functions. The company was founded on August 19, 1998 and is headquartered in London, Canada.
- Employees
- 17
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- CA81732W1041
- Primary Ticker
- SVA